Valor202020212022202320242025TTMDespesas comerciais, gerais e administrativas10.47 B9.63 B10.04 B10.5 B10.82 B10.73 B10.88 BPesquisa e desenvolvimento13.56 B12.24 B13.55 B30.53 B17.94 B15.79 B24.76 BLucro operacional4.29 B10.64 B14.1 B-437 M17.47 B18.36 B8.48 BLucro não operacional, total1.14 B2.69 B-2.3 B27 M845 M484 M275 MDespesa com juros, líquida de juros capitalizados831 M806 M962 M1.15 B1.27 B1.36 B1.52 BReceitas não operacionais, líquidas das despesas com juros-578 M545 M-1.76 B-653 M-450 M-722 M-924 MReceitas/despesas incomuns886 M1.34 B-1.5 B-466 M24 M-151 M-324 MLucro antes dos impostos8.79 B13.88 B16.44 B1.89 B19.94 B21.07 B11.63 BParticipação no lucro———————Impostos1.71 B1.52 B1.92 B1.51 B2.8 B2.8 B2.69 BParticipação de minoritários15 M16 M7 M12 M16 M9 M0Outras receitas/despesas após impostos49 M-805 M-1.3 B-355 M-510 M-511 M-422 MLucro líquido antes das operações descontinuadas7.07 B12.34 B13.81 B-342 M17.12 B18.25 B8.94 BOperações descontinuadas—707 M707 M707 M———Lucro líquido7.07 B13.05 B14.52 B365 M17.12 B18.25 B8.94 BAjuste de diluição———————Dividendos de ações preferenciais———————Lucro líquido diluído disponível aos acionistas7.07 B13.05 B14.52 B365 M17.12 B18.25 B8.94 BLucro básico por ação2.795.165.730.146.767.33.57Lucro diluído por ação2.785.145.710.146.747.283.55Número médio de ações básicas2.53 B2.53 B2.53 B2.54 B2.53 B2.5 B—Ações diluídas2.54 B2.54 B2.54 B2.55 B2.54 B2.51 B—EBITDA7.91 B13.85 B18 B3.44 B21.97 B24.2 B14.73 BEBIT4.29 B10.64 B14.1 B-437 M17.47 B18.36 B8.48 BCusto da receita15.48 B13.63 B17.41 B16.13 B15.19 B16.38 B17.16 BOutros componentes do custo———————Amortização e depreciação (fluxo de caixa)3.63 B3.21 B3.91 B3.87 B4.5 B5.84 B6.25 B
Merck & Company, Inc. Common Stock
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue.
The company's revenues are primarily from cancer treatments, vaccines, and animal health products. In 2024, 46% of the company's revenue, or $29.5 billion, came from sales of Keytruda, a PD-1 inhibitor used to treat various types of cancers, and 13% of the company's revenue, or $8.6 billion, came from sales of Gardasil, an HPV vaccine. In addition, 9% of the company's revenue, or $5.8 billion, came from the sales of animal health products.
The company is ranked 65th on the Fortune 500 and 76th on the Forbes Global 2000.
In 1891, Merck & Co. was established as the American affiliate of the Merck Group, founded by the Merck family, and the companies are still in trademark disputes in several countries over the right to use the name "Merck".